AANP PMHNP EXAM QUESTIONS AND CORRECT DETAILED ANSWERS (VERIFIED
ANSWERS) |ALREADY GRADED A+||BRAND NEW VERSION 2026!!!
Question 1
A Psychiatric-Mental Health Nurse Practitioner (PMHNP) completes an evidence-based quality
improvement project and plans to disseminate the findings. Which of the following
dissemination methods represents the highest level of scholarly dissemination?
A) Presenting a poster board at an institutional grand rounds
B) Publishing the findings in a peer-reviewed academic journal
C) Leading an informal discussion during a department journal club
D) Presenting a 30-minute podium lecture at a regional nursing chapter
E) Delivering an invited presentation at an annual national professional conference
Correct Answer: B) Publishing the findings in a peer-reviewed academic journal
Rationale: Dissemination communicates research findings to broader clinical audiences.
Publication in a peer-reviewed academic journal provides the highest level of scholarly
dissemination because manuscripts undergo rigorous blinded peer review and reach
permanent, international indexing. Podium presentations at national conferences rank
second, followed by regional presentations, local grand rounds, and journal clubs.
Question 2
A PMHNP administers the Mini-Mental State Examination (MMSE) to a 72-year-old client
presenting with memory decline. The client scores 17 out of 30. How should the PMHNP
interpret this score?
A) Normal age-related cognitive functioning
B) Mild cognitive impairment
C) Moderate cognitive impairment
D) Severe end-stage dementia
E) Inconclusive cognitive performance
Correct Answer: C) Moderate cognitive impairment
Rationale: The Mini-Mental State Examination (MMSE) is scored from 0 to 30: 24–30
indicates normal cognition, 19–23 denotes mild cognitive impairment, 10–18 indicates
moderate cognitive impairment, and 0–9 indicates severe cognitive impairment. A score of
17 falls within the moderate cognitive impairment range.
Question 3
A 28-year-old female with bipolar I disorder is maintained on lamotrigine 200 mg daily. The
client presents with acute trigeminal neuralgia, and the neurologist prescribes carbamazepine.
How does carbamazepine affect lamotrigine metabolism?
A) Carbamazepine inhibits CYP2C19, doubling lamotrigine serum levels.
B) Carbamazepine induces hepatic glucuronidation, decreasing lamotrigine serum levels.
, 2
C) Carbamazepine displaces lamotrigine from serum albumin, causing acute toxicity.
D) Carbamazepine competitively blocks renal lamotrigine excretion.
E) Carbamazepine exerts no pharmacokinetic effect on lamotrigine clearance.
Correct Answer: B) Carbamazepine induces hepatic glucuronidation, decreasing
lamotrigine serum levels.
Rationale: Carbamazepine is a potent broad-spectrum hepatic enzyme inducer (affecting
CYP3A4 and UDP-glucuronosyltransferases). Lamotrigine is primarily metabolized via
glucuronidation. Adding carbamazepine significantly increases lamotrigine clearance and
can reduce its serum concentrations by approximately 50%, requiring an upward dosage
adjustment of lamotrigine.
Question 4
A 22-year-old female client stabilized on lamotrigine 150 mg daily for bipolar depression
initiates combined oral contraceptive pills (estrogen-progestin). What pharmacokinetic
interaction should the PMHNP anticipate?
A) Oral contraceptives inhibit CYP3A4, causing toxic elevations in lamotrigine levels.
B) Ethinyl estradiol induces UGT1A4 glucuronidation, reducing lamotrigine levels by up to
50%.
C) Progestins decrease lamotrigine renal clearance, causing cutaneous hypersensitivity.
D) Lamotrigine elevates circulating estrogen levels, increasing the risk of thromboembolism.
E) No pharmacokinetic interaction occurs between oral contraceptives and lamotrigine.
Correct Answer: B) Ethinyl estradiol induces UGT1A4 glucuronidation, reducing
lamotrigine levels by up to 50%.
Rationale: Ethinyl estradiol is a potent inducer of the UDP-glucuronosyltransferase
(UGT1A4) enzyme system responsible for lamotrigine clearance. Initiating combined oral
contraceptives can lower circulating lamotrigine concentrations by approximately 50%,
potentially precipitating depressive or manic relapses unless the lamotrigine dose is
increased.
Question 5
In clinical research biostatistics, what constitutes a Type I error (𝛼)?
A) Failing to reject the null hypothesis when an actual clinical difference exists (false negative)
B) Rejecting the null hypothesis when no true difference exists in the population (false positive)
C) Selecting an unrepresentative study sample due to voluntary response bias
D) Applying a two-tailed statistical test when a one-tailed test was protocol-specified
E) Failing to enroll a sample size adequate to achieve 80% statistical power
Correct Answer: B) Rejecting the null hypothesis when no true difference exists in the
ANSWERS) |ALREADY GRADED A+||BRAND NEW VERSION 2026!!!
Question 1
A Psychiatric-Mental Health Nurse Practitioner (PMHNP) completes an evidence-based quality
improvement project and plans to disseminate the findings. Which of the following
dissemination methods represents the highest level of scholarly dissemination?
A) Presenting a poster board at an institutional grand rounds
B) Publishing the findings in a peer-reviewed academic journal
C) Leading an informal discussion during a department journal club
D) Presenting a 30-minute podium lecture at a regional nursing chapter
E) Delivering an invited presentation at an annual national professional conference
Correct Answer: B) Publishing the findings in a peer-reviewed academic journal
Rationale: Dissemination communicates research findings to broader clinical audiences.
Publication in a peer-reviewed academic journal provides the highest level of scholarly
dissemination because manuscripts undergo rigorous blinded peer review and reach
permanent, international indexing. Podium presentations at national conferences rank
second, followed by regional presentations, local grand rounds, and journal clubs.
Question 2
A PMHNP administers the Mini-Mental State Examination (MMSE) to a 72-year-old client
presenting with memory decline. The client scores 17 out of 30. How should the PMHNP
interpret this score?
A) Normal age-related cognitive functioning
B) Mild cognitive impairment
C) Moderate cognitive impairment
D) Severe end-stage dementia
E) Inconclusive cognitive performance
Correct Answer: C) Moderate cognitive impairment
Rationale: The Mini-Mental State Examination (MMSE) is scored from 0 to 30: 24–30
indicates normal cognition, 19–23 denotes mild cognitive impairment, 10–18 indicates
moderate cognitive impairment, and 0–9 indicates severe cognitive impairment. A score of
17 falls within the moderate cognitive impairment range.
Question 3
A 28-year-old female with bipolar I disorder is maintained on lamotrigine 200 mg daily. The
client presents with acute trigeminal neuralgia, and the neurologist prescribes carbamazepine.
How does carbamazepine affect lamotrigine metabolism?
A) Carbamazepine inhibits CYP2C19, doubling lamotrigine serum levels.
B) Carbamazepine induces hepatic glucuronidation, decreasing lamotrigine serum levels.
, 2
C) Carbamazepine displaces lamotrigine from serum albumin, causing acute toxicity.
D) Carbamazepine competitively blocks renal lamotrigine excretion.
E) Carbamazepine exerts no pharmacokinetic effect on lamotrigine clearance.
Correct Answer: B) Carbamazepine induces hepatic glucuronidation, decreasing
lamotrigine serum levels.
Rationale: Carbamazepine is a potent broad-spectrum hepatic enzyme inducer (affecting
CYP3A4 and UDP-glucuronosyltransferases). Lamotrigine is primarily metabolized via
glucuronidation. Adding carbamazepine significantly increases lamotrigine clearance and
can reduce its serum concentrations by approximately 50%, requiring an upward dosage
adjustment of lamotrigine.
Question 4
A 22-year-old female client stabilized on lamotrigine 150 mg daily for bipolar depression
initiates combined oral contraceptive pills (estrogen-progestin). What pharmacokinetic
interaction should the PMHNP anticipate?
A) Oral contraceptives inhibit CYP3A4, causing toxic elevations in lamotrigine levels.
B) Ethinyl estradiol induces UGT1A4 glucuronidation, reducing lamotrigine levels by up to
50%.
C) Progestins decrease lamotrigine renal clearance, causing cutaneous hypersensitivity.
D) Lamotrigine elevates circulating estrogen levels, increasing the risk of thromboembolism.
E) No pharmacokinetic interaction occurs between oral contraceptives and lamotrigine.
Correct Answer: B) Ethinyl estradiol induces UGT1A4 glucuronidation, reducing
lamotrigine levels by up to 50%.
Rationale: Ethinyl estradiol is a potent inducer of the UDP-glucuronosyltransferase
(UGT1A4) enzyme system responsible for lamotrigine clearance. Initiating combined oral
contraceptives can lower circulating lamotrigine concentrations by approximately 50%,
potentially precipitating depressive or manic relapses unless the lamotrigine dose is
increased.
Question 5
In clinical research biostatistics, what constitutes a Type I error (𝛼)?
A) Failing to reject the null hypothesis when an actual clinical difference exists (false negative)
B) Rejecting the null hypothesis when no true difference exists in the population (false positive)
C) Selecting an unrepresentative study sample due to voluntary response bias
D) Applying a two-tailed statistical test when a one-tailed test was protocol-specified
E) Failing to enroll a sample size adequate to achieve 80% statistical power
Correct Answer: B) Rejecting the null hypothesis when no true difference exists in the
